Antitetanus Vaccination for People Older Than 65 Years.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

261 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-09

Study Completion Date

2017-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the last ten years, more than one hundred generalized tetanus cases were declared in France. Most of them were affecting people older than 70 years with an important mortality (around 28%). It is know that the only way to protect ourselves from this disease is the vaccination. In France tetanus vaccination is mandatory since 1940.

Nowaday none study looked specifically for the vaccination of people older than 65 years. The hypothesis is: there is a difference in the tetanus vaccination coverage for people older than 65 years depending on the demographic and medical practice of their general practitioner.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older

NCT00457249

Pertussis Tetanus Diphtheria

COMPLETED PHASE4

Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial

NCT07112144

Prevent Whooping Cough Prevent Diphtheria Prevent Tetanus

RECRUITING PHASE3

Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE

NCT01546909

Diphtheria Tetanus Poliomyelitis

COMPLETED PHASE4

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

NCT02587520

Tetanus Diphtheria Pertussis +1 more

COMPLETED PHASE1/PHASE2

Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine

NCT03552445

Tetanus Diphtheria Pneumococcal Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tetanus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.

Questionnaire Patients

Intervention Type OTHER

Patient will have to answer a quiz which is about their vaccination against tetanus.

General practitioner

General practitioner of the Auvergne-Rhônes-Alpes region

Questionnaire General practitioner

Intervention Type OTHER

General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire Patients

Patient will have to answer a quiz which is about their vaccination against tetanus.

Intervention Type OTHER

Questionnaire General practitioner

General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 65 years consulting their attending physician in and who agreed to participate in the study.
* The doctors included are general practitioners located in a liberal office in the "Auvergne Rhône Alpes" region for which the URPS ("Union régional des Professionnels de Santé") has an email address.